Where Protagonist’s anti-IL23 fits in the oral psoriasis landscape

The efficacy of injectable IL-23 therapies for psoriasis remains unmatched, with the first Phase II readout for an oral therapy against the target — JNJ-77242113 from Protagonist and Johnson & Johnson — failing to reach the same level of psoriasis clearance based on the primary endpoint measure.

However, the peptide therapy does appear competitive with other new oral therapies on the market and in development for the indication, and stands out on a secondary outcome measure that’s becoming increasingly important for psoriasis drug development: Psoriasis Area Severity Index 100 (PASI 100)...